In a clinical trial sponsored by the National Cancer Institute (NCI), it was revealed that low doses of steroids can prove to be effective for the treatment of bone marrow cancer rather than being administered with dexamethasone.

The trial pointed out that low dosage regimen of steroids (dexamethasone) with lenalidomide can prove to be an excellent option for patients who are suffering from newly diagnosed multiple myeloma. The trial also indicated that a combination of lenalidomide and dexamethasone bring fewer side-effects than a standalone or combination of other medication.

From Bio-Medicine.Org:

Multiple myeloma is a cancer of plasma cells that are found in blood and bone marrow.

Survival chances improved considerably when a low dose of the steroid dexamethasone combined with lenalidomide was tried on patients with newly diagnosed multiple myeloma.

The clinical trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG).

The significance of the results lies in that a low dose regimen has been found to be more effective than the standard dose of dexamethasone.

Researchers found that patients in the study who received a lower dose regimen had a one-year survival of 96 percent compared to 86 per cent for patients treated in the case of those with the standard-dose of dexamethasone and lenalidomide.

In addition, there were fewer side effects associated with the low-dose dexamethasone and lenalidomide.

As per noted study chair Vincent Rajkumar, a combination of lenalidomide plus low-dose dexamethasone can prove to be an effective option for multiple myeloma.

Children who are suffering from Childhood Nephrotic Syndrome and administered with steroid drugs do not suffer from bone loss, as per a recently published study.

This syndrome, which affects three out of every one hundred thousand children, is believed to be the most common form of chronic kidney ailment in young children. It is considered to weaken ability of a young body by eliminating the presence of water and salt from the blood. This elimination results in swelling of the belly, legs, and region around eyes.

As per pediatric nephrologist Mary B. Leonard, M.D., of The Children’s Hospital of Philadelphia and lead author of the study, the nephrotic syndrome can be effectively and easily treated with steroid therapy when compared to treatment for other child diseases treated with steroid drugs.

From News-Medical.net:

The team led by Dr. Leonard compared 60 children and adolescents with steroid-sensitive nephrotic syndrome to 195 healthy children. Specialized X- ray measurements showed no signs of osteoporosis, a loss in bone mass, among the nephrotic syndrome patients. The study appeared in the August 26 New England Journal of Medicine.

The researchers made adjustments for body mass index, an important consideration, since 38 percent of the children in the nephrotic syndrome sample were obese (in contrast, only 16 percent of the control subjects were obese, a proportion consistent with the general pediatric population). The disproportionate obesity among children with nephrotic syndrome disappears after the patients discontinue steroid treatments.

“While steroids tend to make children shorter and heavier than healthy children, increased weight is associated with an increase in bone mass,” said co-author Babette Zemel, Ph.D., of the Nutrition Center at Children’s Hospital. Specifically, whole-body measurements of bone mineral content were higher in children with nephrotic syndrome than in healthy children.

A possible explanation for the increased bone mass, she added, is that the extra physical load imposed by higher weight may stimulate the bones to grow stronger. Obesity may also induce hormones to increase bone mass.

Bone health in childhood strongly influences bone health in later life- including the degree to which older adults are vulnerable to osteoporosis- related fractures. “This report may help reassure doctors and parents that using steroids to treat children with nephrotic syndrome does not raise their risk of osteoporosis,” said Dr. Leonard. “There is some evidence that obesity raises a child’s risk of fracture, but this may be due to the force of a heavy child falling on an outstretched arm-and not to a weakening of the bone.”

It was noticed during the study that complete body measurements of the bone mineral content of children suffering from this syndrome was higher than that of the healthy children, as per co-author of this study, Babette Zemel, Ph.D., of the Nutrition Center at Children’s Hospital.

Inhaled corticosteroids may not be sufficient in controlling asthma on both children and adults. The study made by Dr. Gregory Sawicki showed that some children may not be able to keep their asthma under control even if they consistently use inhaled corticosteroids.

The study of 914 children with mild to moderate asthma found that over a one-year period, children who reported consistent inhaled steroid use were 20% less likely to report having well-controlled asthma compared with those not using any inhaled steroids.

From Medical News Today:

“There may be several reasons for our findings; It is possible that some children are genetically less responsive to steroids,” says researcher Gregory Sawicki, M.D. of Children’s Hospital in Boston. “In addition to issues of medication adherence and inability to completely control for differences in underlying asthma, severity can never be completely ruled out.”

Several studies of adults with asthma have suggested that even rigorous use of inhaled steroids doesn’t lead to well controlled asthma in all adults, Dr. Sawicki noted. “Further studies are needed to see what is different about children who don’t respond to steroids, to see if there is a way to predict whether a child will respond to inhaled steroids.”

Of the 914 children in the study, inhaled steroids were recommended for 435 who had persistent asthma, meaning they had symptoms on a regular basis. Among children who weren’t recommended for inhaled steroid treatment, most reported well-controlled asthma. Among those recommended for inhaled steroid treatment, 44% reported consistently using the medicine; 35% said they intermittently used the medicine and 21% said they didn’t use it at all.

Doctor Sawicki says that the findings of the study provide realistic views on how asthma is being managed. This study suggests that both parents and physicians should make sure that children adhere to their inhaled steroid treatment.

A study made a group of Dutch researchers showed that an epidural injection of steroids with a local anesthetic did not provide the long-term pain relief doctors anticipated for patients suffering from post-herpetic neuralgia. According to Dr. Albert J.M. van Wijck, epidural steroid injection only reduces pain for one month.

The study involved nearly 600 patients 50 or older, with acute herpes zoster rash and significant pain. Half received standard therapy (oral antivirals and analgesics), and half received standard therapy plus an epidural injection of 80 mg of methylprednisolone acetate and 10 mg of bupivacaine.

From Medpage today:

At one month, significantly fewer patients in the epidural group reported zoster-associated pain (relative risk=0.83; 95% confidence interval=0.71-0.97; P=0.02).

By three months, however, there was not a clear significant difference between the groups (RR=0.89; 95% CI=0.65-1.21; P=0.47), and by six months, the end of the study period, the effect had disappeared altogether, the researchers said.

For the time being, the Dutch team recommended the more burdensome approach of hospitalizing patients with chronic severe shingles pain that is not responding to standard treatment. There, giving corticosteroids and anesthetics via an epidermal catheter for one to three weeks may be the best option, the authors suggested. Recent research has shown this approach to be effective, they added.

The lack of efficacy demonstrated by this study shows “that the invasive procedure of epidural injection with steroids and local anesthetics in herpes zoster—which is commonly used in many countries—cannot be recommended.

The results suggested that the single epidural injection approach which is used by many clinicians should be reserved for treating severe, acute shingles pain in patients not responding to standard analgesic therapy. They also pointed out that giving corticosteroids and anesthetics via an epidermal catheter for one to three weeks may be the best option to provide relief.

As per a recently concluded study, inhaled corticosteroids are more effective than sodium cromoglycate for treating asthma along with helping a lending hand to the lung to function in a normal way.

The study remarked that the superiority of inhaled corticosteroids tends to increase with its moderate low doses, compared to its low doses, as per Dr James Guevara, Department of Pediatrics at the University Of Pennsylvania School Of Medicine in Philadelphia and lead review author of this study.

From News.Bio-Medicine.org:

Inhaled corticosteroids (ICS) and sodium cromoglycate (SCG) are both used to help people with asthma. SCG is believed to have a low risk of causing long-term side effects, but despite anxieties relating to routine use of steroids, the use of ICS has steadily increased since the 1990s.

While they are both known to work, there has previously been a debate as to whether one is superior to the other.

By pooling data from randomized controlled trials that directly compared the effects of ICS and SCG the Cochrane Review Authors could assess the relative benefits of each. They considered measures of lung function, asthma control and the use of general healthcare services such as GPs and hospitals.

Their conclusion was that ICS controls asthma better than SCG and that it also leads to improved lung function. They were, however, unable to decide whether there were differences in side-effects as most of the trials ran for too short a time to assess long-term outcomes.

“The superiority of ICS over SCG appears to increase when patients use moderate doses of ICS, compared with when low doses of ICS are used,” says lead Review Author Dr James Guevara, who works in the department of Pediatrics at the University of Pennsylvania School of Medicine in Philadelphia.

Inhaled Corticosteroids have the ability to control asthma in a better manner than sodium cromoglycate and seems to be a better option for patients with asthma, DR Guevara concluded.

The study is believed to benefit almost more than one million asthma patients in the United States alone. This study has been accepted by the medical fraternity as a new ray of hope for future treatment developments in asthma management.

The group of scientists has found out that the steroid produced by Gordonia cholesterolivorans can be useful in pharmaceutical and medical sectors in the future. Aside from producing a useful steroid compound, Gordonia bacteria also has the ability to break down cholesterol which could be used to clean up contamination.

The reasearch team tries to work out exactly how Gordonia cholesterolivorans metabolize cholesterol so they can identify and construct metabolically engineered strains that are more rapid and effective in breaking down cholesterol.

From Medical News Today:

A novel species of bacteria with cholesterol-busting properties has been discovered by scientists at the Universidad Complutense de Madrid, Spain. Dr Oliver Drzyzga and colleagues isolated the new bug, called Gordonia cholesterolivorans, from sewage sludge.

Gordonia bacteria have only been classed as a separate group of bacteria since 1997 but they have already proved useful as they are able to degrade a wide range of environmental pollutants including phthalates (used in plastics), rubber and hazardous compounds such as the explosive hexogen (cyclotrimethylenetrinitramine). Gordonia cholesterolivorans’ ability to break down cholesterol means that it could be used to clean up contamination.

Dr Drzyzga and co-workers are studying the genetics of this novel bacterium to genetically modify strains that might also be used to synthesise new and industrially useful breakdown products of cholesterol.

“New steroid compounds made by these bacteria may find applications in the pharmaceutical and medical sectors in the future, but as some Gordonia species are pathogenic to humans it is unlikely that they could be used directly to treat high cholesterol-related conditions in humans”, said Dr Drzyzga.

The team of Dr. Oliver Drzyzga found out about the cholesterol-busting properties of Gordonia by isolating the bacteria from the sewage sludge. Although this species of bacteria can break down cholesterol, it cannot be used to treat cholesterol-related illnesses in humans.

In a recent study, it was remarked that the short-term application of topical corticosteroids and maintenance with a less potent agent can help patients fighting against intertriginous psoriasis (IP).

The study was conducted by Alexander Kreuter, M.D, from Ruhr University of Bochum, Germany, and colleagues.

From Bio-Medicine.Org:

In this study, Alexander Kreuter, M.D, from Ruhr University of Bochum, Germany, and colleagues conducted a randomized controlled trial that compared 1 percent pimecrolimus (a new anti-inflammatory drug), 0.005 percent calcipotriol, 0.1 percent betamethasone and the vehicle (a similarly appearing cream with no active drug) in the treatment of IP with a four-week treatment period and a six-week follow-up without therapy. A total of 80 adult patients with the clinical diagnosis of IP were included, 20 patients in each of the four treatment groups.

“After four weeks of treatment, the three active compounds and the vehicle resulted in a significant decrease in mean (average) M-PASI score [Modified Psoriasis Area and Severity Index] (86.4 percent for 0.1 percent betamethasone, 62.4 percent for 0.005 percent calcipotriol, 39.7 percent for 1 percent pimecrolimus and 21.1 percent for vehicle),” the researchers found. “The 0.1 percent betamethasone was significantly more effective than 1 percent pimecrolimus during the study period.”

The above findings are believed to offer relief to all those patients who have been suffering from intertriginous psoriasis (IP) and complaining of soreness, intense itching, and irritation from sweating.

It was previously believed that the application of topical corticosteroids has some side-effects when used in long-term but this study has completely refuted such beliefs.

To sum up, it was remarked during the study that the short-term application of corticosteroids for acute disease followed by a maintenance treatment with a less potent agency can be regarded as a reasonable approach for IP treatment.

Budesonide, a steroid nasal wash, can help in minimizing the symptoms of chronic sinusitis without affecting adrenal gland functions, as per a small US Study.

Chronic Sinusitis refers to a continuing inflammation of the nose and sinuses behind it that affects up to 14 percent population of the United States.

Researchers from the Washington University School of Medicine in St. Louis remarked that the study was the first one to scrutinize safety of such a nasal wash. The study also noted that suppression of the functions of the adrenal gland is a known barrier of Budesonide.

From Bio-Medicine.Org:

All participants reported at least some improvement in their sinusitis symptoms, and their adrenal gland function was not affected, the study found. The results were published in the March issue of Otolaryngology – Head & Neck Surgery.

“The clinical significance of this study is that budesonide nasal respules appear safe for short-term use for the relief of symptoms associated with chronic sinusitis,” the researchers concluded. “Budesonide respules seem to provide an effective treatment option for the patient with chronic rhinosinusitis with minimal fear of systemic adverse effects.”

The FDA has yet to give nod to this drug as a nasal wash and this means that nasal wash of this study would be an off-label use of Budesonide.

In the meanwhile, researchers advised the medical fraternity to advise patients about the possible risks associated with long-term usage of Budesonide such as decreased bone mineral density.

In a recent study, it was remarked that older asthmatic women who are on inhaled steroids are less likely to die from any ailment over five years when compared to women not using any kinds of inhaled steroids.

Two recent studies from Canada suggested that inhaled steroid therapy has benefits beyond the lungs, as per Dr. Carlos A. Camargo Jr., from Massachusetts General Hospital, Boston, and colleagues.

From Reuter.com:

Their findings stem from 2,671 women with persistent asthma participating in the Nurses’ Health Study who responded to a 1998 supplementary asthma questionnaire. Fifty-four percent of these women reported inhaled steroid use in 1998.

Over the next five years, 87 women (3.3 percent) died. Twenty two women died of cardiovascular causes, 31 from cancer, and 34 died from “other” causes (including 4 from asthma).

According to Camargo and colleagues, use of inhaled steroid therapy at the outset, relative to non-use, was associated with a significant 42 percent reduced likelihood of dying from any cause and a 65 percent reduced likelihood of dying from a heart-related cause.

During the study, it was remarked that the apparent non-pulmonary benefits of inhaled steroids remained continue to stay strong after the researchers controlled for different factors that had the abilities to possibly influence the research results.

The above findings clearly suggested that benefits of an early inhaled steroid therapy in the long run have the unique ability to go much beyond asthma management in an effective manner.

As per a recently concluded study, it was revealed that children being administered with inhaled corticosteroids such as budesonide in the past have not been able to show those improvements after stopping the steroid treatment. These results were observed after the Childhood Asthma Management Program (CAMP) clinical trial announced its findings on more than 1,000 children in the age group of 5-12 years.

During the study, it was found that children (now in their late teens) who have been advised steroid therapy in the past and stopped now showed no differences in management of asthma when they were compared with children who received the placebo.

Robert C. Strunk, M.D., a Washington University pediatrician at St. Louis Children’s Hospital and lead author of the study, said that it was quite interesting to note that children tend to do better with the passe of age when it comes to combating asthma.

Inhaled corticosteroids such as budesonide have been regarded as one of the most effective forms of anti-inflammatory treatments for controlling asthma via improving pulmonary function.

From Sciencedaily.com:

“While the kids did get better with age and didn’t seem to need the medicine as much, laboratory measurements indicated that they were still having symptoms, and therefore were primed to an attack if they got a bad cold or were exposed to a significant weather change,” Strunk said.

The researchers determined that continued benefit of these medications likely requires continued use.

“The conclusion is that some kids get better, but the doctor, family and the patient have to pay attention to the symptoms,” Strunk said. “Some of the kids are going to need medicine, and they have to be honest about that possibility.”

In another part of the follow-up study, researchers looked at long-term side effects of the steroid medications on growth, bone density and fracture rate. The only side effect of budesonide was a 0.4-inch decrease in height among female patients compared to the patients who took a placebo during the trial. However, one-fourth of the girls and more than half of the boys in the trial had not reached final adult height at the end of the post-trial period, researchers said. There were no effects of the nedocromil treatment on growth.

Funding from the National Heart, Lung, and Blood Institute and the National Center for Research Resources supported this research.

The study also suggested that if an asthma patient gets cured after being administered with steroid treatment then he should not stop the treatment presuming that asthma is completely cured. It was found that continued benefits of steroid medications require continued usage.

As per the latest study conducted by researchers from the National Institute of Allergy and Infectious Diseases, it was found that low doses of hydrocortisone (steroid) can bring slight improvements in patients suffering from chronic fatigue syndrome (CFS) symptoms but at the cost of a possible risk to adrenal suppression.

Stephen E. Straus, M.D., Chief of the Laboratory of Clinical Investigation at NIAID and Senior Author on the study commented that the kind of adrenal suppression in context of the steroid seems to be justified for treatment of CFS patients.

From News.Bio-Medicine.Org:

“The data show that about half the people on placebo and two-thirds of those taking hydrocortisone reported some improvement in well-being,” comments Stephen E. Straus, M.D., chief of the Laboratory of Clinical Investigation at NIAID and senior author on the study. “The greater benefit seen in the hydrocortisone group, however, was modest, and there was clear evidence of adrenal suppression by the drug.” Twelve of 33 patients on the therapy developed laboratory evidence of adrenal insufficiency. “It was manageable and completely reversible,” says Dr. Straus, “but it’s the kind of suppression that in the context of minimal improvement afforded by the drug cannot, in our minds, justify using this treatment for CFS.

The study was closely watched by the medical world with a hope that the troubling woes of CFS patients will finally come to an end. But, the risk of suppression is a bit of a concern. This is the reason why Strauss is further testing fludrocortisone in 100 patients with CFS and neurally mediated hypotension with his team so that the potential danger of adrenal suppression can be completely outplayed.

In the study headed by Prof. Shanna Swan, pregnant women who eat beef are prone to have sons with unhealthy sperm counts. Other findings related to this study revealed that expectant mothers who consumed more than seven beef meals in a week had sons whose sperm concentration was 24% less compared to men whose mothers had consumed less beef during their pregnancy.

According to Prof. Swan, the findings in the study published in the journal Human Reproduction, suggest that beef consumption is associated with lower sperm counts and concentration which leads to possible sub-fertility because of the presence of anabolic steroids and other xenobiotics in beef.

From Bio-Medicine:

The sperm counts have been record low among men in the western nations due to their exposure to pesticides and industrial chemicals. The growth promoters used in cattle is thought to be behind the low sperm counts. The most recent study involving men in the United States born between 1949 and 1983, revealed that expectant mothers who consumed more than seven beef meals in a week had sons whose sperm concentration was 24% percent less compared to men whose mothers had consumed less beef during their pregnancy.

Prof Shanna Swan, the lead author of the study published in the journal Human Reproduction, said: “These findings suggest that maternal beef consumption is associated with lower sperm concentration and possible sub-fertility, associations that may be related to the presence of anabolic steroids and other xenobiotics in beef. Theoretically, the fetus and young children are particularly sensitive to exposure to sex steroids. Therefore, the consumption of residues of steroids in meat by pregnant women and young children is of particular concern.”

These findings urged pregnant women not to eat too much beef, especially those with treated with anabolic steroids, because fetus and young children are sensitive to exposure to sex steroids.

Inhaled corticosteroids are proven safe on bones. This was the finding of Jordana Schmier and his colleagues in their review of more than 260 studies. The group reviewed both published and unpublished literature and selected 14 studies that met their criteria. Majority of the studies reviewed included patients who received moderate to high doses of corticosteroid therapy.

From Bio-Medicine:

Previous studies have shown inhaled corticosteroids can decrease a person’s bone mineral density. However, researchers now say long-term use of ICS therapy is not associated with a significant change in BMD.

Corticosteroids are commonly used to treat asthmatics and people with chronic obstructive pulmonary disorder. Researchers say these medications are good at reducing inflammation and mucus production in the airways of the lungs.

Jordana Schmier and colleagues examined more than 260 studies and presented their findings at the Annual Scientific Assembly of the American College of CHEST Physicians in Orlando, Fla. They reviewed both published and unpublished literature and selected 14 studies that met their criteria. Researchers say the majority of the studies reviewed included patients who received moderate to high doses of corticosteroid therapy.

Results show long-term use of these medications by patients with asthma or COPD was not associated with significant changes in BMD. Schmier says using ICS therapy is important in controlling symptoms of various lung disorders. She concluded, “ICS treatment at standard doses in patients with asthma or COPD does not have a clinically meaningful effect on BMD.”

The researchers claim that inhaled corticosteroids do not cause significant effects on bone mineral density (BMD) of the patients. This conclusion was contrary to the findings of the previous studies which linked corticosteroids to bone loss.

Corticosteroids are prescribed to asthmatic patients and people with chronic obstructive pulmonary disorder (COPD) because these drugs reduce inflammation and mucus production in the airways of the lungs.

American reporters, after doing an integrated survey showed that there has a great increase in the use of steroids by school girls in America. All the girls which were using steroids were not necessarily the athletes or a sports player but were keen on getting their bodies in proper shape like all models and actors.

All these girls are heading towards testosterone pills mainly with eating disorders. These anabolic steroids thus are working to a level that it can actually make them look younger and fitter.

From CBS news:

An alarming number of American girls, some as young as 9, are using bodybuilding steroids — not necessarily to get an edge on the playing field, but to get the toned, sculpted look of models and movie stars, experts say.

Girls are getting their hands on the same dangerous testosterone pills, shots and creams that have created a scandal in major league baseball and other sports. Often, these are the same girls who have eating disorders, according to some research.

Already most of these girls are getting bigger and stronger on the field for their respective games since there is a huge increase in the participation of girls in sports past years. Jeff Hoerger, from Rutgers University in New Jersey said that it was seen women were using these steroids to as a weight control and body fat reduction.

Above all if you want steroids to work on you , you need to start from third grade itself as ninth grade will be too late to be quiet effective to you in that age ,as said by Small.

Also parents and adults should be aware of asking youngsters about possible steroid use to avoid its risk as it can be harmful if carelessly consumed.